# MedBrain: A Novel Deep Learning Tool for Holistic Patient Data Interpretation and Clinical Event Prediction

Anand, Suraj

#### 0 Abstract

Approximately 55,000 patients are treated daily in Intensive Care Units (ICUs) within the United States. Clinical decision making for such patients requires rapid yet holistic patient data review. However, with copious patient chart data (vitals, diagnoses, labs, notes, and prescriptions), there is information overload, leading to slower care and poorer outcomes. Current Computer-Aided Diagnostic solutions are used minimally, as they either lack interpretability or are unable to provide meaningful insight into patient data relationships.

MedBrain is an interpretable deep learning framework created to improve clinician decision-making by predicting significant clinical events and identifying relevant patient variables based on chart data. Models were trained on time-series patient data from Beth Israel Hospital (2001-2012) after manual preprocessing via outlier detection, imputation, and quality control. Natural language processing algorithms were constructed to incorporate diagnoses and note embeddings into the dataset. Multiple Long Short Term Memory (LSTM) Recurrent Neural Networks with Attention were engineered to predict future likelihood of critical short-term events of mortality, sepsis, vancomycin antibiotic administration, and myocardial infarction.

These achieved an Area under the Receiver Operating Characteristic (AUROC) curve of 0.94, 0.88, 0.83, and 0.80, respectively (>0.80 signifies robust model). Attention maps allowed the novel discovery of unknown patient-variable interactions, such as diuretic *furosemide* as an early predictor of sepsis. Moreover, analysis of diagnosis embeddings enables physicians to evaluate for possible overlooked diagnoses associated with the patient's past diagnoses.

This innovative prediction model harnesses the power of deep learning while providing unprecedented explainability via attention mechanisms, reducing information overload by distilling vast patient data to show only relevant variables. Consequently, MedBrain's robust clinical decision support could potentially improve care efficacy, speed, and cost.

#### 1 Introduction

Each day, around 55,000 patients are treated in Intensive Care Units (ICUs) within the United States. These patients possess an average length of stay of 3.80 days with a mortality rate between 10-29%; furthermore, the operation of their stays in ICUs costs about 82 billion dollars per year (Halpern NA, Pastores SM 2005). This tremendous number of patients produces a great excess of real-time and historical patient data that may, at times,

overload medical staff. This data requires quick analysis as the patient acuity is unknown and may be hazardous. Further, physicians spend an inordinate amount of time comprehending patient history via notes, charts, etc to create an accurate diagnosis and prognosis. This procedure requires holistic analysis of patient history and features; for instance, a patient with abdominal pain may be due to appendicitis, gallstones, gallbladder inflammation, or a

myriad of other causes. Often, personalized patient features assist in properly diagnosing patients. By prioritizing the exhibition of high-value patient features, the amount of available data to sift through diminishes significantly. In turn, decreased information overload occurs, which is connected to quicker patient process times as well as fewer errors (Ahmed 2011).

Prioritization of data may occur in various forms; most commonly, although not uniformly widespread, a scoring system of patient features. These systems, such as the APACHE II (Acute Physiology And Chronic Health Evaluation II) score or the SOFA (Sequential Organ Failure score. aid practitioners Assessment) determining the acuity of the patient's condition (Suistomaa M, et al 2002). They consist of integer-based scoring operations that account for various patient features. Moreover, machine learning algorithms like logistic regression and single-layer perceptrons are increasingly useful in clinical decision making: these algorithms have proved to be beneficial in predicting survival and hospital stay length. However, many of these models were trained on a specific of data. and demographic thus lack generalizability. In addition, these models do not account for time-varying data, often lack interpretability, and possess a selection of features a priori thereby not allowing usage of the full gambit of collected features (Kaji D, et al. 2019).




Figure 1: Possible Causes of Abdominal Pain (Fogoros 2019)

These issues may be averted by utilizing sequential deep learning techniques and interrogating them. A real-time interactive prediction of mortality and intervention strategies would provide physicians with an interpretable framework to synthesize patient condition. My research will focus on developing a time-to-event clinical event prediction as well as identifying relevant patient features for diagnosis/prognosis. Recent advances in this field have introduced a variety of deep learning techniques for time-to-event prediction. Notably, the novel self-attentive Attend and Diagnose model improves predictive accuracy for mortality and disease but does not examine interpretability (Song, et al 2017).



Figure 2: The Attend and Diagnose model hierarchy that utilizes a simple self-attention mechanism to enable sequence formation without recurrence (Song, et al 2017).

#### 2 Methods

This research worked to develop intelligent methods to identify major clinical events and interpret patient charts, vitals, and notes. As such, it was split into a few accumulation of data. stages: preprocessing exploration, and experimentation of classical techniques, experimentation of deep learning techniques, and thorough analysis. First, a preliminary literature review was conducted to accumulate information about clinical events, current prediction methods, and possible model structures. This stage of the study allowed a full immersion into the present field of research, which better enables feature engineering and analysis when constructing a model.

#### 2.1 Data

To garner data for this project, the Citi Program Human Subjects Biomedical Course was completed. Next, the PhysioNet database was reached out to in order to acquire the MIMIC III dataset (Medical Information Mart for Intensive Care III). This is a "large, database comprising de-identified health-related data associated with over forty thousand patients who stayed in critical care units of the Beth Israel Deaconess Medical Center between 2001 and 2012." (MIMIC III). This dataset possesses distinct 38,597 adult patients and 49,785 hospital admissions. Within this data is demographics, vitals, lab tests, chart events, physician notes, results, procedures, medications, caregiver notes, imaging among and mortality other reports, information; it is widely regarded as the

preeminent healthcare patient chart database. Once downloaded, this dataset was integrated into a postgresql database to provide organization, access, and storage.

Current research focuses on mortality prediction. While this research shows promising results, it does not provide physicians with the interpretability necessary to explain these results -- consequently, the output of such "blackbox models" is rendered purposeless due to a variety of bias and Furthermore, training concerns. while mortality prediction yields accurate results, in practice, this score may not be a good indicator of clinical deterioration. That is why this study places special emphasis on clinical events and developing interpretable models (via SHAP and attention mechanisms) that highlight important patient features in clinical decision making; concomitantly, the physician may confirm, correct, or deny model outputs.

#### 2.2 EDA/Preprocessing

Exploratory data analysis was conducted to acquire a familiarity with the dataset and problem. This would enable a far more productive preprocessing step. In this step, histograms were created of salient features such as age, sex, admission location, etc. Any patient that was assigned an age over 300 (done for de-identification) reassigned an age of 89. Additionally, neonatal patients were excluded from this study. Frequency histograms of microbiology, lab, and chart events were plotted to discern the most relevant events (in an attempt to condense the dataset size without losing pertinent information). Only the most frequently-occuring eight microbiology events, twenty lab events, and twenty chart events were utilized in this study. Further, this

data was linked via the item id variable back to the eponymous value. Certain predictor variables that strongly correlated with the response and were rare in practice were excluded from the dataset (troponin in myocardial infarction modeling, vancomycin administration in vancomycin modeling) to avoid conventional solutions. The data was grouped into chunks of 12-hour, 24-hour, 48-hour, and all data and the mean, max, and min of each variable was calculated. Another one-hot encoded vector corresponding to the hospital location with the diagnosis was appended to this vector. Additionally, the remaining hospital stay length or remaining time until deceasement was computed for the survival analysis model. Features with over 75% of the data missing were removed and values over the 95% percentile were replaced with the median (as there is the presence of erroneous measurements). This exploration and preprocessing occurred using primarily the pandas, numpy, and matplotlib libraries.

For all experiments, 80% of the data was designated to the training set and 20% of the data was designated to the validation set. All models were trained on the training set and hyperparameter tuned by viewing metrics of evaluation on the validation set. To reduce the class imbalance, positive sampling of the positive class occurred.

#### 2.3 Models

Initially, a simple Gradient Boosted Trees Model was employed by the *XGBoost* library employing all solely structured data to predict mortality. This model acted as a baseline from which to compare more advanced models.

From here, the datasets were split into the 12-hour available data, 24-hour available data,

48-hour available data, and all data. Separate gradient boosted trees were trained to predict mortality of the patients at these different times in the patients stay. Various metrics of evaluation including specificity, sensitivity, the area under the precision-recall curve, the area under the receiver operating characteristic curve were analyzed. Moreover, Shapley Explanatory Values (SHAP) were examined via a mix of Summary Plots, Force Plots, and Dependency Plots to ensure model veracity as well as to view interactions between models. Generalized Additive Model was constructed and trained on the identical dataset. This model was scrutinization using Microsoft's InterpretML Library Interface. Graphical Finally, a cox-proportional hazards model was then employed (aka a survival analysis model) to predict the time until release or deceasement.

- 1. Initialize  $f_0(x) = \arg\min_{\gamma} \sum_{i=1}^{N} L(y_i, \gamma)$ .
- 2. For m = 1 to M:
  - (a) For  $i = 1, 2, \ldots, N$  compute

$$r_{im} = -\left[\frac{\partial L(y_i, f(x_i))}{\partial f(x_i)}\right]_{f=f_{m-1}}.$$

- (b) Fit a regression tree to the targets  $r_{im}$  giving terminal regions  $R_{jm}, j = 1, 2, ..., J_m$ .
- (c) For  $j = 1, 2, \ldots, J_m$  compute

$$\gamma_{jm} = \arg\min_{\gamma} \sum_{x_i \in R_{jm}} L\left(y_i, f_{m-1}(x_i) + \gamma\right).$$

- (d) Update  $f_m(x) = f_{m-1}(x) + \sum_{j=1}^{J_m} \gamma_{jm} I(x \in R_{jm})$ .
- 3. Output  $\hat{f}(x) = f_M(x)$ .

Figure 3: Gradient Trees Algorithm

This model, the most sophisticated of those so far, incorporated the sequential nature of the data into consideration. SHAP values were calculated and analyzed.

Next, more sophisticated techniques were attempted. First, four deep feed-forward

networks were constructed in Keras to predict the mortality at different times within the patient stay. These were modified to predict the onset of Sepsis, Myocardial Infarction, and Vancomycin Antibiotic Administration. Following this alteration, unstructured note data was vectorized event with Bidirectional Encoder Representations from Transformers (BERT) model to extract sentence vector representations. A skip gram was created to convert each one-hot encoded diagnosis vector into a 36-dimensional embedding. Each sentence's numeric representation in a hospital admission was summed, and this was appended to each patient's vector of structured data. Then, multiple Long Short Term Memory (LSTM) Recurrent Network were optimized with attention mechanisms. The attention vector works to learn weight by utilizing the context of the input vector, where weights corresponding to features are found to focus the next layer of the model on certain features. These features may be extracted to find high activation functions feature-pairings, leading to a much higher interpretability. After this network was constructed and modified, hyperparameter tuning was conducted. Furthermore, the salient patient characteristics that drive a clinical event prediction were extracted via analysis of the hidden layer activation functions. A myriad of metrics (AUC, AUPRC, Specificity, Sensitivity, F1, etc) were evaluated on these networks.

#### 3 Results

Baseline Gradient Boosted Trees (XGBoost) mortality prediction models were tested for performance at the 12-hour patient stay mark, the 24-hour patient stay mark, the 48-hour patient stay mark, and 1-hour before departure/deceasement. Metrics of evaluation included the area under the Receiver Optimizer Characteristic (ROC) curve, the area under the Precision-Recall Curve, and the accuracy.

The ROC curve plots the false positive rate versus the true positive rate at different decision thresholds, describing how well the model can differentiate between patients who will survive their stay and those who will not. The metric of the area under the ROC curve lies between 0 and 1. Values that are closer to 1 indicate a better predictive value. The Precision-Recall curve plots precision vs. recall at various predictor thresholds, describing the tradeoff between true positive rate and positive predictive power. This curve is more aptly suited to describe imbalanced datasets, such as MIMIC-iii mortality (only ~10% samples are positive).

The 12-hour-mark-predictor XGBoost model achieved an Area under the ROC (AUROC) of 0.803 (applicable models > 0.80). In addition, the Area under the Precision-Recall Curve (AUPRC) was 0.344, presenting a concave up curve with acceptable precision and recall in middle decision boundary ranges. In contrast, the 24-hour-mark-predictor XGBoost model achieved an AUROC of 0.826 and an ofAUPRC 0.359 The 48-hour-mark-predictor XGBoost model

achieved an AUROC of 0.841 and an AUPRC of 0.417. Finally, the XGBoost model using all data except the hour before the conclusion of data collection achieved an AUROC of 0.939 and an AUPRC of 0.634. The Precision-Recall curve of this model is notable as it is concave-down, indicating better performance in practice (however, it must be noted that predicting mortality an hour before the event does not empower the clinician to take effective preventative measures). When the SHapley Additive exPlanations (SHAP) values were analyzed among these models, age, anion gap mean, and platelet count min were found to be the preeminent predictors of mortality at the 12-hour mark; age, anion gap mean, and urea nitrogen min were found to be the preeminent predictors of mortality at the 24-hour mark; age, urea nitrogen min, and bicarbonate mean were found to be the preeminent predictors of mortality at the 48-hour mark; at the hour mark, peripheral capillary oxygen saturation min, heart rate min, and systolic blood pressure min were found to be the preeminent predictors of mortality.

The Generalized Additive Model yielded similar results with an AUROC of 0.93 (predicting using all data except for the last hour). This model displayed peripheral capillary oxygen saturation min, heart rate min, age, anion gap mean, and urea nitrogen min as with the highest variable importance.

The constructed cox-proportional hazards model (survival analysis) model, which employs a parametric approach to determine the timing and occurrence of events, performed ably, with a concordance

statistic, or C-statistic, of 0.75. This metric of evaluation determines the fraction of concordant pairs, or patient pairs for which the outcome and the order of deceasement/departure is predicted SHAP value examination correctly. exhibited age, oxygen saturation min, and urea nitrogen min to be paramount indicators of the predicted time-to-event.

deep feed-forward network predicting data from the 12-hour mark attained an AUROC of 0.931 on the validation set, the network using 24-hour data reached an AUROC of 0.941 on the validation set, the network using 48-hour data reached an AUROC of 0.951 on the validation set, and the network using all data except the last hour reached an AUROC of 0.971 on the validation set (attesting to the power of deep learning). Among these models, age, mean corpuscular hemoglobin concentration, anion gap minimum, urea nitrogen minimum, chloride minimum, heart rate minimum, and systolic minimum were found to be the most influential patient features.

The skip gram of the diagnosis embeddings cannot be evaluated with traditional techniques as it unsupervised tool to visualize diagnosis embeddings. However. based off rudimentary relationship analysis, the vector space exhibits signs of captured semantic meaning (e.g. diagnosis vectors such as diabetes and high blood sugar are closer than diagnosis such as pregnancy and concatenation cancer). After the ofembedded note event data to the patient vectors, the trained clinical event Long Short Term Memory (LSTM) Recurrent Neural Networks possessed next-day predictive AUROC of 0.881 for sepsis, 0.832 for MI, and 0.841 for vancomycin administration. Pulled attention maps were able to highlight individual prediction variable influences.

This pipeline of mortality prediction, clinical event prediction, and then chart/vital/note interpretation is highly effectual, producing a fully-automated model for patient short-term risk and long-term risk prediction.

Overall, the clinical event predictor, with a GBM survey accuracy of 85.13% and an Ensemble CNN accuracy of 87.16% on validation sets, producing a fully-automated model for high-risk lung cancer candidate selection and malignant pulmonary nodule detection/assessment.

#### 4 Discussion

MedBrain's amelioration of detection and management ofmortality, sepsis. vancomycin antibiotic administration, and myocardial infarction is crucial to improving ICU outcomes. The engineered LSTM with attention mechanisms was able to achieve AUCs indicative of applicable value (>0.80) in modeling eventual clinical deterioration via the aforestated events. As expected, the models received an advantage from more data; thus the networks utilizing 48-hours worth of data and networks utilizing all data except the last hour performed better than those of 12 and 24 hours worth of data.

Models developed for unstructured data preprocessing possess standalone value. The patient diagnoses embeddings may assist in ensuing physician diagnosing of patients. Given the inherent spatial associations in this medical vector space, physicians may use cosine similarity as a metric to examine possible diagnoses frequently found with the patient's current/past diagnosis. In addition, the note embeddings developed via the fine-tuned BERT model provide insight into critical words and pairings. The highlighting of these critical words and phrases could allow clinicians to process past notes at a much faster rate.

The strong performance in mortality prediction may be attributed to the LSTM's ability to model time-series data and form deep contextual relationships facilitated by attention. As such, MedBrain's AUROC of 0.94 greatly exceeds the most widely used ICU mortality prediction score, APACHE II, which achieves an AUROC of 0.77 (from retrospective cohort study conducted by Polita et al.). Upon analysis of the model on the validation dataset, there were discernible differentiators between the LSTM when predicting on the patients 12-hour data, 24-hour data, 48-hour data, and all data except the last hour. Notably, while age possessed the highest variable importance in the first three of these models, in the last model the best predictor of ultimate was the mortality minimum oxygen saturation percentage (SpO2). Nevertheless, this is likely as clinical deterioration has already begun in patients by the last hour; thus, the minimum SpO2 percentage of these patients may fall dramatically, suggesting that the patient is close to expiration. The developed system better detects high-risk patients and better captures

obscure/unfamiliar variable relationships, especially beneficial in unusual cases.

Sepsis prediction obtained high predictive value, likely because variables in the Systemic Inflammatory Response Syndrome (SIRS) criteria that were a component of the calculation for presence of Sepsis were located in the dataset. Additionally, a variety of antibiotics signalled infection; the attention maps identified powerful antibiotics like vancomycin and ceftriaxone as indicators of sepsis. Prediction of future vancomycin antibiotic administration also achieved robust success. This may be due in part as vancomycin is often administered to treat sepsis. Moreover, from activations extracted from the attention maps and SHAP values, it may be theorized that antibiotics such as cefazolin and diuretics such as furosemide that were given beforehand are proxies for administration. vancomycin Finally, myocardial infarction models performed well, but with less precision, as there were far fewer strong predictors (no EKG, chest pain analysis, etc) and far fewer patients with a positive condition. The model's ability to predict a new heart attack was also hindered as medications utilized in MI treatment are also utilized to treat long-term heart disease. Nonetheless, this model retains value in application as the sensitivity was reasonable and attended variables were confirmed as pertinent in literature.

MedBrain effectively aids in providing urgent decision-making support by predicting clinical events and distilling holistic patient data to those germane to present care. Variable-level attention maps

and SHapley Additive exPlanations (SHAP) values unveil the once "blackbox" of this deep learning model. Without this layer of transparency, these predictions would be unusable; as physicians would have no way of identifying the driving patient variables to stage interventions and there would be no proper method to ensure that there are no biases/warps in the model.

Overall, this prediction could allow more accurate and expeditious detection of patients at high-risk for mortality, sepsis, myocardial infarction or in need of vancomycin administration, engendering better intervention. Such models may also aid in identifying potentially unfamiliar, yet important, predictive variables from eclectic patient inputs. By diminishing information overload, clinicians may better parse patient relationships; consequently, data efficacy would increase and use of gunshot testing may be reduced, thereby improving cost. The combined MedBrain is a formative system for intelligent clinical decision-making support.

#### 4.1 Future Research

Future research is necessary. As the onset of significant clinical events (e.g. Sepsis) may occur rapidly, it would be beneficial to predict clinical events on an granular of real-time basis. Furthermore, contextual decomposition should be explored in healthcare to show physicians whether a variable increases or decreases risk. Finally, other visualization options could provide a more succinct summary of salient patient feature.

#### References

Halpern NA, Pastores SM. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010;38(1):65–71. pmid:19730257

Gruenberg DA, Shelton W, Rose SL, Rutter AE, Socaris S, McGee G. Factors influencing length of stay in the intensive care unit. Am J Crit Care. 2006;15(5):502–509. Pmid:16926372

Ahmed A, Chandra S, Herasevich V, Gajic O, Pickering BW. The effect of two different electronic health record user interfaces on intensive care provider task load, errors of cognition, and performance. Crit Care Med. 2011;39(7):1626–1634. pmid:21478739

Suistomaa M, Niskanen M, Kari A, Hynynen M, Takala J. Customised prediction models based on APACHE II and SAPS II scores in patients with prolonged length of stay in the ICU. Intensive Care Med. 2002;28(4):479–485. pmid:11967604

Polita, Jorge Roberto, Gomez, Jussara, Friedman, Gilberto, & Ribeiro, Sérgio Pinto. (2014). Comparison of APACHE II and three abbreviated APACHE II scores for predicting outcome among emergency trauma patients. *Revista da Associação Médica Brasileira*, 60(4), 381-386. https://dx.doi.org/10.1590/1806-9282.60.04.018

Changhee Lee, William R. Zame, Jinsung Yoon, and Mihaela van der Schaar. Deephit: A deep learning approach to survival analysis with competing risks. In Association for the Advancement of Artificial Intelligence. 2018.

Alistair E.W. Johnson, Tom J. Pollard, Lu Shen, Li wei H. Lehman, Mengling Feng, Mohammad Ghassemi, Benjamin Moody, Peter Szolovits, Leo Anthony Celi, and Roger G.

Mark. MIMIC-III, a freely accessible critical care database. Scientific Data, 3, 2016. Article number: 160035.

Johnson, A., & Mark, R. G. (2018). Real-time mortality prediction in the Intensive Care Unit. *AMIA* ... *Annual Symposium proceedings*. *AMIA Symposium*, 2017, 994–1003.

Zhengping Che, Sanjay Purushotham, Kyunghyun Cho, David Sontag, and Yan Liu. Recurrent neural networks for multivariate time series with missing values. Sci. Rep., 8(1), 2018.

Halpern NA, Pastores SM. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010; 38(1):65–71. https://doi.org/10. 1097/CCM.0b013e3181b090d0 PMID: 19730257

Ahmed A, Chandra S, Herasevich V, Gajic O, Pickering BW. The effect of two different electronic health record user interfaces on intensive care provider task load, errors of cognition, and performance. Crit Care Med. 2011; 39(7):1626–1634. https://doi.org/10.1097/CCM.0b013e31821858a0 PMID: 21478739

Suistomaa M, Niskanen M, Kari A, Hynynen M, Takala J. Customised prediction models based on APACHE II and SAPS II scores in patients with prolonged length of stay in the ICU. Intensive Care Med. 2002; 28(4):479–485. https://doi.org/10.1007/s00134-002-1214-9 PMID: 11967604

Evran T, Serin S, Gurses E, Sungurtekin H. Various scoring systems for predicting mortality on intensive care unit. Niger J Clin Pract. 2016;19:530-534.

Kaji DA, Zech JR, Kim JS, Cho SK, Dangayach NS, Costa AB, et al. (2019) An attention based deep learning model of clinical events in the intensive care unit. PLoS ONE 14(2): e0211057. https://doi.org/10.1371/journal.pone.0211057

Song H, Rajan D, Thiagarajan JJ, Spanias A. Attend and Diagnose: Clinical Time Series Analysis using Attention Models. CoRR. 2017;abs/1711.03905.

Fogoros, Richard N. "Abdominal Pain - When To See A Doctor." Verywell Health, Verywell Health, 5 Nov. 2019, <a href="https://www.verywellhealth.com/abdominal-pain-when-to-see-a-doctor-1745398">https://www.verywellhealth.com/abdominal-pain-when-to-see-a-doctor-1745398</a>.

Lee, J., Yoon, W., Kim, S., Kim, D., Kim, S., So, C. H., & Kang, J. (2019). BioBERT: a pretrained biomedical language representation model for biomedical text mining. Bioinformatics. doi: 10.1093/bioinformatics/btz682

H. Nori, S. Jenkins, P. Koch, and R. Caruana. Interpretml: A unified framework for machine learning interpretability. arXiv preprint arXiv:1909.09223, 2019.

Tianqi Chen and Carlos Guestrin. Xgboost: A scalable tree boosting system. In Proceedings of the 22Nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, pages 785–794. ACM, 2016.


## Appendix


Variables	Scores	Variables	Scores
Heart Rate	Carl Water	Ht (%)	
≤ 54	5	< 0	9
55-69	1	20-29.9	2
70-109	O	30-45.9	0
110-139	1	46-59.9	0 2 9
≥ 140	5	> 60	9
Respiratory Rate		WBC( $\times$ 10 <sup>3</sup> /mm <sup>3</sup> )	
≤ 5	10	< 2.9	3
11-Jun	2	3-19.9	0
24-Dec	0	≥ 20	3
25-34	2	GCS	
35-49	6	3	12
≥ 50	10	4	11
If FIO, ≥ 0.5:(A-a)O	(mmHg)	5	10
< 00	0	6	9
200-349	2	7	8
≥ 350	3	8	7
If $FIO_2 < 0.5$ :(A-a)	O <sub>a</sub> (mmHg)	9	6
< 6Ô	7	10	5
≥ 61	O	11	4
PH		12	3
< 7.24	4	13	3 2 1
7.25-7.32	O	14	1
7.33-7.59	2	15	0
≥ 7.6	4	Chronic Organ Insufficiency	
		immune-compromised and:	
Age		AND TAKEN IN LABOUR	
≤ 44	0	Non-Operative	3
45-74	2	Emergency-postoperative 3	
≥ 75	6	Elective-Postoperative	2
	Total So	core Sum of scores	

<sup>\*</sup>Ht: Hematocrit, WBC: White blood cells count, GCS: Glasgow coma score


### LIMITED

Appendix Figure 1: APACHE II System Used





Appendix Figure 2: Gradient Boosted Tree Extracted (1 out of 50)



Appendix Figure 3: Diagnoses Embeddings Visualized

diuresis), Nitropaste [\*\*1-3\*\*]", and Lovenox 80 mg SQ. During the free since. Presenting vitals BP 109/66, HR 71, O2 sat 88% on RA. CXR when he woke up feeling cold; 1 hour later he developed moderate to about every day to every other day and have been stable over the past dyspnea and is relieved with few minutes rest. His symptoms occur outside or to walk to the bedroom). The pain is associated with lb cat, carrying 1 gallon jug of water, first getting up from sitting to walk to pain he had last night) with fairly minimal exertion (picking up his 11 attributes to osteoarthritis. But he says that he gets chest pain (similar 1858\*\*] has very poor exercise tolerance due to knee pain that he IVF for ? low BP). On further questioning, Mr. [\*\*Known lastname ambulance transfer to the [\*\*Hospital1 18\*\*], he also received ~500 cc at 0.4, CK 70. He given aspirin and furosemide 80 mg IV (with ~600cc showed congestive heart failure; initial troponin-I was mildly elevated not resolve until he was given SL NTG at 6 am by EMS. He has been pain nausea, diaphoresis, and dypsnea. The pain was fairly constant and did severe sharp chest pain radiating across his chest associated with He states he was in his usual state of health until 10:30 last evening

about every day to every other day and have been stable over the past ambulance transfer to the [\*\*Hospital1 18\*\*], he also received ~500 cc showed congestive heart failure; dyspnea and is relieved with few minutes rest. His symptoms occur outside or to walk to the bedroom). The pain is associated with attributes to osteoarthritis. But he says that he gets chest pain (similar diuresis), Nitropaste [\*\*1-3\*\*]", and Lovenox 80 mg SQ. During the severe sharp chest pain radiating across his chest associated with when he woke up feeling cold; 1 hour later he developed moderate to to pain he had last night) with fairly minimal exertion (picking up his 11 1858\*\*] has very poor exercise tolerance due to knee pain that he IVF for ? low BP). On further questioning, Mr. [\*\*Known lastname free since. Presenting vitals BP 109/66, HR 71, O2 sat 88% on RA. CXR not resolve until he was given s.L. NTG at 6 am by EMS. He has been pain nausea, diaphoresis, and dypsnea. The <mark>pain</mark> was fairly constant and did He states he was in his <mark>usual</mark> state of <mark>health</mark> until 10:30 last evening lb cat, carrying 1 gallon jug of water, first getting up from sitting to walk <mark>t 0.4, CK 70</mark>. He given <mark>aspirin</mark> and <mark>furosemide</mark> 80 mg IV (with ~600cc

Appendix Figure 4: Highlighting of Critical Words/Phrases Via Attention

```
Chief Complaint: Transferred s/p vertebroplasty s/p respiratory\n failure\n HPI:\n 64 year old man with ESRD on hemodialy sis (from FSGS) last vertexday.\n HCV, CAD w/stent, HTN and newly diagnosed metastatic poorly\n differentiated cancer (likely
sis (from FSGS) last vesterday in HCV, CAD w/stent, HTN and newly diagnosed metastatic poorly in differentiated cancer (likely NSCLC) presenting from PACU after re-intubation post vertebronlests, for respiratory distress. Briefly, other presented [**1-19**] with shortness of breath, which has resolved over the course of admission. On recent CT scan (to rule out PE), his dise
              was noted to be "substantially progressed" since his last CT less than\n one month prior. In addition, he had a patholo
gic fracture of T4 noted\n on the same CT, and he was noted to have DVT on LE ultrasound and that\n time placed on drip. [**1-31**] transferred to the OMED for\n chemotherapy targeted toward his progressive cancer. Scheduled for\n
                                                                                                                                                                                                                                time placed on a heparin
                                                                                                                                                                                                                                                                 vertebrop
             of T4 once INR <1.5, therefore for vertebroplasts today.\n ...\n During vertebroplasts, BP, VS stable on ventilation. Min lood\n loss. Received 1350 cc crystalloid, no urine output as expected.\n Extubed, and at 16:30 rolled into PACU with o
          blood\n
2 sats 90%10 L with\n reported difficulty moving air. Nasal trumpet inserted, pt suctioned\n scant amount. RR 16. Ten minutes
later no improvement in status, 80% on\n
                                                                                           10L, HR 110\'s-120\'s, face mask placed and pt reintubated. Propoful\n restarted. CX
R with worsening pulmonary edema, no focal opacities.\n Discussed with renal team, to be staffed in AM.\n Patient admitted fr
om: PACU\n History obtained from Medical records\n Patient unable to provide history: Sedated\n Allergies:\n Penicillins\n Rash;\n Adhesive Tape (Topical)\n Rash;\n Last dose of Antibiotics:\n Infusions:\n Propofol - 25 mcg/Kg/min\n Hep arin Sodium - 1,100 units/hour\n Other ICU medications:\n Other medications:\n Metronidazole 500mg PO BID (last day [**2198])
 -2-4**])\n Lisinopril 20mg PO daily\n Nifedipine CR 30mg PO daily\n Metoprolol 100mg PO BID\n ASA 325mg PO daily\n
ix (held)\n Isosorbide Mononitrate 30mg PO daily\n Acetylcysteine Neb Q6H PRN\n Albuterol Neb Q6H PRN\n
                                                                                                                                                                                                                                                Ipratropium Neb Q
6H PRN\n Acetaminophen 1000mg PO Q8H\n Nephrocaps\n Calcium Acetate 667mg TID with meals\n Pantoprazole 40mg PO BID\n Oxycodone SR 40mg PO Q8H\n Oxycodone 5-10mg PO Q4H: PRN\n Docusate 100mg PO BID\n Senna\n Epoietin Alfa at dialysis\n Gu aifenesin\n Past medical history:\n Family history:\n Social History:\n PMHX:\n #. Onc HX: [**12-11**] pre-renal transp
lant CT scan chest noted enlarged RML\n nodule, w/ subcentimeter FDG avid scattered lymph nodes. Developed neck\n pain and fo und to have C2 pathological fracture, [**11-22**] cytology\n demonstrated poorly differentiated carcinoma. Likely non-small cel
In lung carcinoma, with RML mass and metastasis to the cervical and sacral\n spine. The only manifestation of his disease rrently is cervical neck\n pain, s/p pathologic fracture and posterior cervical arthrodesis C1-C3\n and palliative XRT. Hol ng on chemo as access issues.\n #. CAD s/p angioplasty D1 [**7-10**] and stents to OM2/3 in [**3-11**]\n #. ESRD secondary FSGS on HD (MWF)\n #. Hypertension\n #. LLE peroneal nerve palsy [**1-6**] GSW to L leg\n #. Thalassemia trait\n #. h/c
                                                                                                                                                                                                                                and palliative XRT. Holdi
                                                                                                                                                                                                                                           #. ESRD secondary to
                                                                                                                                                                                                              #. Thalassemia trait\n #. h/o S
FSGS on HD (RWF)\n #. Hypertension\n #. LLE peroneal nerve palsy [**1-b**] GSW to L leg\n #. Thalassemia trait\n #. h/o wbstance abuse (heroin/cocaine); reports none since [**2163**]\n #. CHF w/ EF 35% in [**11-11**], EF 25-30% on [**Data Range ** ] [**2198-1-23**]\n #. MR - 2+ on [**Month/Day/Year **] in [**11-11**]; now found to be 3+ MR [**First Name (Titles) **] [**Las t Name (Titles) **] #. Pathological C2 Fx s/p Cl-3 Fusion\n #. Parotiditis - [**12-12**] (levo/flagy)\n #. CDiff - [**12-12**] (levo/flagy)\n #. CDiff - [**12-12**] n #. HCV - grade 1 inflammation and stage 0 fibrosis on bx [**2-9**]\n NC\n Occupation:\n Drugs:\n Tobacco:\n Alcohol:\n Other: lives with girlfriend, has 2 sons, used to work in construction,\n + smoker 1 PPD for many years quit recen
tly, rare ETOH, no drugs.\n Review of systems:\n Flowsheet Data as of [**2198-2-2**] 07:39 AM\n Vital Signs\n Hemodynamic
monitoring\n Fluid Balance\n
Since 12 AM\n Tmax: 36.4\nC
                                                                                                                                                                                                               24 hours\n
0 mL\n
                                                                                                                                                                    0 mL\n
                                                                                                                                                                                     Urine:\n NG:\n Stool:\n Drains:\n
lance:\n
                                                                                                                                                                         0 mL\n
                           Respiratory\n Ventilator mode: CMV/ASSIST\n Vt (Set): 550 (550 - 550) mL\n RR (Set): 14\n RR (Spontaneous):
0\n PEEP: 5 cmH20\n FiO2: 50%\n RSBI: 21\n PIP: 20 cmH20\n Plateau: 18 cmH20\n SpO2: 100%\n ABG: //25\\n Ve: 6.8 L/min\n Physical Examination\n General Appearance: Well nourished\n Eyes / Conjunctiva: constricted pupils bilaterally\n
Head, Ears, Nose, Throat: Normocephalic, Endotracheal tube\n Cardiovascular: (S1: Normal), (S2: Normal), (Murmu: Systolic)\n
Peripheral Vascular: (Right radial pulse: Present), (Left radial pulse:\n Present), (Right DP pulse: Not assessed), (Left DP pulse: Not assessed)\n Respiratory / Chest: (Expansion: Symmetric), (Breath Sounds: Crackles :\n ), anterior, scant crackles\n
Abdominal: Soft, Bowel sounds present\n Extremities: Right: Absent, Left: Absent\n Skin: Not assessed, No(t) Rash: ,No(t) J aundice\n Neurologic: Responds to: Unresponsive, Movement: Not assessed, Sedated,\n Tone: Not assessed\n Labs / Radiology\n 275 K/uL\n 7.2 g/dL\n 80 mg/dL\n 5.9 mg/dL\n 32 mg/dL\n 25 mEq/L\n 99 mEq/L\n 4.8 mEq/L\n 136 mEq/L\n 23.7 %\n 7.5 K/uL\n [image002.jpg]\n [**2195-12-7**]\n 2:33 A2/29/[**2197]
                                                                                                          [**2195-12-11**]\n
**1 03:12 AM\n
                                                                                                                                                                                                                           10:20 P\n
[**2195-12-12**]\n
                                                                                                                                                                                                             [**2195-12-13**]\n
                                                                                                                  1:20 P\n
11:50 P\n
                                                                                            [**2195-12-14**]\n
                                                                                                                                                                                                                1:20 A\n
  **2195-12-15**]\n
                                                                                          7:20 P\n
[**2196-1-7**]\n
                                                                                                                                                                                                         1//11/006\n
1:20 P\n
 1:23 P\n
 [**2196-1-7**]\n
                                                                                                             11:20 P\n
                                                                                                                                                                                                           [**2196-1-7**]\n
                                                                                                                                                                                                                        23.7\n Plt\n
0.10\n Glucose\n
4:20 P\n
                     WBC\n
                                                                                                                  7.5\n Hct\n
4:20 Pyn WBCyn


75 Nn Cr\n

75 Nn TropT\n


75 Nn Tr
                     # Acute respiratory failure: post extubation after 1300 cc fluids in\n anuric patient with depressed EF. Also conside
r aspiration, pt also\n lethargic therefore sedation also could be contributing. No clear\n evidence for PE, though patient w
r aspiration, pt also: retinary the relative security and the DVT on IV heparin until 6AM. Pt\n also with severe lung disease given CA\n -co y decrease Fi02.\n -discussed with renal HD tomorrow AM to remove fluid as overloaded\n
          LE DVT on IV heparin until 6AM. Pt\n also with severe lung disease given CA.\n -continue on vent, with last gas can likel crease Fi02.\n -discussed with renal HD tomorrow AM to remove fluid as overloaded\n -CXR in AM\n -CX data\n -Extubate pulmonary edema improved, propofol weaned.\n .\n #Pump: CHF, systolic dysfunction EF 25-30%. Anuric with 1+ liter fluid. No LE edema, sparse crackles, cannot assess JVP given neck collar.\n Evidence of worsening pulmonary edema on radiology.\n
once pulmonary edema improved, propofol weaned.\n
                                                                                                                                 # Metastatic NSCLC. plan was to receive navelbine [**1-30**], but co
                                                        -HD today as per renal.\n
                                                                                                                      .\n
-continue cardiac meds\n -HD today as per renal.\n .\n # Metastatic NSCLC. plan was to receive navelone [--1-30-], but to uld not\n receive [**1-6**] no access.\n - discussion with oncology regarding time of continued treatment\n - discussion of access for chemo, PICC placement.\n .\n # vertebral fractures: s/p C1-C3 fusion, new T4 compression fracture\n without neur clogic compromise. S/P vertebroplasty\n - NPO\n - heparin gtt was held 6am prior to procedure, will now restart as per\n IR
.\n - continue to wear back and neck collar.\n - C spine collar to continue, can hold when patient eating.\n - Pain control w
ith morphine. To resume PO regimen once extubated.\n .\n # DVT: continue heparin as above, hold coumadin until s/p\n verteb
roplasty. Discussion with IP in AM in terms of time to restart\n coumadin\n .\n # ESRD: HD M/W/F. Discussed with renal tearegarding volume overload.\n Pt to likely undergo dialysis in AM.\n .\n # C-diff +: Continue flagyl. Last day [**2-4**]\n
           # HTN: Holding parameters. Hold nifedipine, to be restarted by team. In\n chart noted patient becomes hypotensive during
dialysis. SBP 95-100 on\n propofol drip.\n
                                                           propofol drip.\n .\n # Anemia: stable.\n -Guaiac all stools\n -on Heparin drip for DVT\n -e # CAD: ROMI negative on admission but MR [**First Name (Titles) **] [**Last Name (Titles) 300**] wors
po with dialysis.\n .\n
compared to 2 months ago. EF was 35-40% and is now 25-30% and MR is 3+\n
                                                                                                                                                                                                                                                      increased from
                                                                                                                                                              -Consider restarting plavix in AM, as vertebroplasty co
mplete.\n .\n # Parotiditis - stone of stentson\'s duct initially seen on [**2197-12-7**],\n patient has passed stone. Levo
                                                              # Hep C: stable, not on treatment.\n .\n # Prophylaxis: Heparin drip/ bowel regimen, cont PPI\n is,\n # comm: wife [**Name (NI) **] [**Telephone/Fax (1) 1284**]\n # Dispo: Pending extubation to
flox/vanco stopped.\n
                                                  .\n
# FEN: NPO, avoiding IV fluids,\n # comm: wife [**Name (NI) **] [**Telephone/Fax (1) 1284**]\n # Dispo: Pending extubation to be called out to OMED\n # Code: Full\n ICU Care\n Nutrition:\n Glycemic Control:\n Lines:\n 20 Gauge - [**2198-2-2**] 02:03 AM\n Prophylaxis:\n DVT: LMW Heparin\n Stress ulcer:\n VAP: HOB elevation\n Comments:\n Communication: Comment s:\n Code status: Full code\n Disposition:\n'
```

Chief Complaint: Transferred s/p vertebroplasty s/p respiratory\n failure\n HPI:\n 64 year old man with ESRD on hemodialy sis (from FSGS) last vesterday.\n HCV, CAD w/stent, HTN and newly diagnosed metastatic poorly\n differentiated cancer (likely by presenting from PACU after\n re-intubation post wertehrolasts for respiratory distress. Briefly, oth presented [\*\*1with shortness of breath, which has resolved over the\n course of admission. On recent CT scan (to rule out PE), his dise NSCLC) presenting from was noted to be "substantially progressed" since his last CT less than one month prior. In addition, he had a patholo gic fracture of T4 noted\n on the same CT, and he was noted to have DVT on LE ultrasound and that\n time placed on a heparin drip. [\*\*1-31\*\*] transferred to the OMED for\n chemotherapy targeted toward his progressive cancer. Scheduled for\n latty of T4 once INR <1.5, therefore for vertabroplatty today.\n ...\n During vertabroplatty, BB, VS stable on ventilation. Min imal blood\n loss. Received 1350 cc crystalloid, no urine output as expected.\n Extubed, and at 16:30 rolled into PACU with o 2 sats 90%10 L within reported difficulty moving air. Nasal trumpet inserted, pt suctionedin scant amount. RR 16. Ten minutes later no improvement in status, 80% onin 10L, HR 110\'s-120\'s, face mask placed and pt reintubated. Propofulin restarted. CX R with worsening pulmonary edema, no focal opacities.\n Discussed with renal team, to be staffed in AM.\n Patient admitted fr om: PACU\n History obtained from Medical records\n Patient unable to provide history: Sedated\n Allergies:\n Penicillins\ Adhesive Tape (Topical) \n Rash; \n Last dose of Antibiotics:\n Infusions:\n Propofol -25 mcg/Kg/min\n arin Sodium - 1,100 units/hour\n Other ICU medications:\n Other medications:\n Metronidazole 500mg PO BID (last day [\*\*2198 -2-4\*\*])\n Lisinopril 20mg PO daily\n Nifedipine CR 30mg PO daily\n Metoprolol 100mg PO BID\n ASA 325mg PO daily\n Plav ix (held) \n Isosorbide Mononitrate 30mg PO daily\n Acetylcysteine Neb Q6H PRN\n Albuterol Neb Q6H PRN\n Ipratropium Neb Q 6H PRN\n Acetaminophen 1000mg PO Q8H\n Nephrocaps\n Calcium Acetate 667mg TID with meals\n Pantoprazole 40mg PO BID\n O xycodone SR 40mg PO Q8H\n Oxycodone 5-10mg PO Q4H: PRN\n Docusate 100mg PO BID\n Senna\n Epoietin Alfa at dialysis\n Gu aifenesin\n Past medical history:\n Family history:\n Social History:\n PMHX:\n #. Onc HX: [\*\*12-11\*\*] pre-renal transp lant CT scan chest noted enlarged RML\n nodule, w/ subcentimeter FDG avid scattered lymph nodes. Developed neck\n pain and fo and to have C2 pathological fracture, [\*\*11-22\*\*] cytology\n demonstrated poorly differentiated carcinoma. Likely non-small cel l\n lung carcinoma, with RML mass and metastasis to the cervical and sacral\n spine. The only manifestation of his disease currently is cervical neck\n pain, s/p pathologic fracture and posterior cervical arthrodesis C1-C3\n and palliative XRT. Holding on chemo as access issues.\n #. CAD s/p angioplasty D1 [\*\*7-10\*\*] and stents to CM2/3 in [\*\*3-11\*\*]\n #. ESRD secondary to FSGS on HD (MWF)\n #. Hypertension\n #. LLE peroneal nerve palsy [\*\*1-6\*\*] GSW to L leg\n #. Thalassemia trait\n #. h/o S ibstance abuse (heroin/cocaine); reports none since [\*\*2163\*\*]\n #. CHF w/ EF 35% in [\*\*11-11\*\*], EF 25-30% on [\*\*Date Range \*\*] [\*\*2198-1-23\*\*]\n #. MR - 2+ on [\*\*Month/Day/Year \*\*] in [\*\*11-11\*\*]; now found to be 3+ MR [\*\*First Name (Titles) \*\*] [\*\*Les) t Name (Titles) \*\*]\n #. Pathological C2 Fx s/p C1-3 Fusion\n #. Parotiditis - [\*\*12-12\*\*] (levo/flagy)\n #. CDiff - [\*\*12-12\*\*]\n #. HCV - grade 1 inflammation and stage 0 fibrosis on bx [\*\*2-9\*\*]\n NC\n Occupation:\n Drugs:\n Tobacco:\n + smoker 1 PPD for many years quit recen Other: lives with girlfriend, has 2 sons, used to work in construction, \n Alcohol:\n tly, rare ETOH, no drugs.\n Review of systems:\n Flowsheet Data as of [\*\*2198-2-2\*\*] 07:39 AM\n Vital Signs\n Hemodynamic monitoring\n Fluid Balance\n Since 12 AM\n Tmax: 36.4\nC 24 hours\n Tmax: 36.4\nC (97.5\n Tcurrent: 35.9\nC (96.6\n HR: 60 (57 - 63) bpm\n BP: 103/54(66) {93/49(60) - 103/54(6 6)} mmHg\n RR: 13 (11 - 15) insp/min\n SpO2: 100%\n Heart rhythm: SR (Sinus Rhythm)\n Height: 67 Inch\n Total I
n:\n 1,465 mL\n PO:\n TF:\n IVF:\n 115 mL\n Blood products:\n 1,350 mL\n Total out:\n
0 mL\n Urine:\n NG:\n Stool:\n Drains:\n Ba 0 mL\n lance:\n 1.465 mL\n Respiratory\n Ventilator mode: CMV/ASSIST\n Vt (Set): 550 (550 - 550) mL\n RR (Set): 14\n PEEP: 5 cmH20\n FiO2: 50%\n RSBI: 21\n PIP: 20 cmH2O\n Plateau: 18 cmH2O\n SpO2: 100%\n ABG: ///25/\n L/min\n Physical Examination\n General Appearance: Well nourished\n Eyes / Conjunctiva: constricted pupils bilaterally\n Head, Ears, Nose, Throat: Normocephalic, Endotracheal tube\n Cardiovascular: (S1: Normal), (S2: Normal), (Murmur: Systolic)\n
Peripheral Vascular: (Right radial pulse: Present), (Left radial pulse:\n Present), (Right DP pulse: Not assessed), (Left DP pulse: Not assessed)\n Respiratory / Chest: (Expansion: Symmetric), (Breath Sounds: Crackles:\n ), anterior, scant crackles\n Abdominal: Soft, Bowel sounds present\n Extremities: Right: Absent, Left: Absent\n Skin: Not assessed, No(t) Rash: , No(t) J aundice\n Neurologic: Responds to: Unresponsive, Movement: Not assessed, Sedated,\n Tone: Not assessed\n Labs / Radiology\n 80 mg/dL\n 5.9 mg/dL\n 32 mg/dL\n 25 mEq/L\n 99 mEq/L\n 4.8 mEq/L\n 136 mEq/L\n 002.jpg]\n (\*\*2195-12-7\*\*)\n 2:33 A2 275 K/uL\n 7.2 g/dL\n [image002.jpg]\n 2:33 A2/29/[\*\*2197 7.5 K/uL\n


·		_			_		
BUN	0.256195	eosinophils_std	0.000000	HDL_max	0.835470	diazepam	-0.174283
HDL	0.835474	glucose_std	0.703436	IN R_max	0.799710	digoxin(?!.*fab)	-0.196570
INR	0.805314	heart rate_std	0.395317	Inspired O2 Fraction_m			4.572023
Inspired O2 Fraction	0.828730	hemocrit_std	3.287776	LDL_max	0.835284	diphenhydramine	-0.267834
LDL	0.835318	hemoglobin_std	6.779672	PEE P Set_max	0.546066	enoxaparin	-0.177901
PEEP Set	0.658234	lymphocytes_std	0000000	PTT_max	0.628405	epoetin	-0.135121
PTT	0.677682	monocytes_std	0.000000	RBCs_max	0.420564	fentanyl	-0.149825
RBCs	0.298982	neutrophils_std	0.000000	WBCs_max	2.357782	fentanyl citrate	-0.391069
WBCs	2015649	platelets_std	-0.215736	anion gap_max	0.792226	fluconazole	-0.183031
anion gap	0.813903	polymorphonuclear leuko	ocytes_std	atypical lymphocytes_n		fondaparinux	-0.046316
atypical lymphocytes	-0.046694	0.000000		bands_max	0.310692	furosemide	1.570308
bands	0.330616	potassium_std	3.350031	basophils_max	0.374720	glucagon	-0.415408
basophils	0.381396	pulse oximetry_std	-0.411423	central venous pressure		halopendol	-0.236200
blood culture	0.836014	respiratory rate_std	0.631375	dnloride_max	0.914430	heparin	0.858553
central venous pressure		sodium_std	-0.322568	creatinine_max	1.694140	hydralazine	-0.344190
chloride	0.911587	systolic_std	0.685980	diastolic_max	0815244	hydrochlorothiazide	-0.162623
creatinine	1785755	temperature (F)_std	0.170085	eosinophils_max	0.473199	hydromorphone	2.402936
daily weight	0825247	tidal volume_std	0.000000	glucose_max	1.159525	insulin	0.917195
diabetes	-0.002113	triglycerides_std	0.0000000	heart rate_max	0.880719	ipratropium	-0.496100
diastolic	1.001999	troponin_std	0000000	hemocrit_max	0.442768	labetalol	-0.196723
eosinophils	0.479636	BUN_min	0.282512	hemoglobin_max	0.411552	levetiracetam	-0.214156
glucose	1.383458	HDL_min	0.835474	lymphocytes_max	0.759415	levofloxacin	-0.359177
heart rate	1.065947	INR_min	0.811202	monocytes_max	0.786099	levothyroxine	-0.346336
hemocrit	0.338775	Inspired O2 Fraction_mir		neutrophils_max	0.840721	lisinopril	-0.330519
hemoglobin	0.303979	LDL_min	0.835244	platelets_max	2.924893	magensium sulfate	1.423270
lymphocytes	0.762092	PEEP Set_min	0.719606	polymorphonudear leul	kocytes_max	meropenem	-0172686
monocytes	0.794781	PTT_min	0.727627	0.839764		metodopramide	-0.342260
neutrophils	0.840921	RBCs_min	0.210973	potassium_max	0.837730	metoprolol	-0.795553
platelets	2.439885	WBCs_min	1.812298	pulse oximetry_max	0.842169	metronidazole	2.884339
polymorphonuclear leu	ikocytes	anion gap_min	0.828858	respiratory rate_max	0.418644	midazolam	-0.320627
0.839994	001600	atypical lymphocytes_mi			0.851164	nafcillin	-0083038
potassium_x	0816422	bands_min	0.338744	systolic_max	1.094195	neostigmine	-0.174589
pulse oximetry	0.839479 0322793	basophils_min	0.386510	temperature (F)_max	0.849977	nitroglycenn	-0.331162
respiratory rate		central venous pressure_i		tidal volume_max	0.801705	nitroprusside	-0.163129
sodium	0.855431	chloride_min	0.912461	triglycerides_max	0.818206	norepinephrine	-0.256707
systolic	1.266889	creatinine_min	1839656	troponin_max	0.058347	ondansetron	2.088988
temperature (F) tidal volume	0.860105 0.810452	diastolic_min	0.845130 0.482936	BLACK AGE	4.143464 0.605534	oxacillin oxycodone	-0.070552 -0.560896
tobacco	-0.015838	eosinophils_min	1.449878		-0.700603	~~~~	1.285861
	0.818678	glucose_min	1.345402	0.9% Sodium Chloride	-0.700603 -0.509534	pantoprazole	-0.056468
triglycerides	0.067443	heart rate_min	0263572		-0.017297	penicillin	-0.030400
troponin BUN_std	-0.261103	hemocrit_min hemoglobin_min	0.226829	SMX-TMP acetominophen	-0.01/29/	phenylephrine phenytoin	-0.320703
HDL_std	0.000000	and the same of th	0.763543	albuterol	1.541824	phytonadione	-0.196153
INR_std	-0.147566	lymphocytes_min monocytes_min	0.797664	amiodarone	-0.293648	piperacillin	-0.190153
Inspired O2 Fraction_s		~~~~	0.840977	amoxicillin	-0.293046	potassium v	1.032929
LDL_std	0.000000	neutrophils_min platelets_min	2.010044	ampicillin-sulbactam	-0.106259	prednisone	3.561686
PEEP Set_std	-0.174930	polymorphonuclear leuko		~~~~~~~~	1.375312	propofol	-0.385592
PTT_std	-0.181870	0.840201	rcytes_mm	asprin atenolol	-0.168326	ranitidine	-0.344811
RBCs_std	-0.103518	potassium_min	1.348165	atropine	-0.204264	statin	-0.710375
WBCs_std	-0.192761	pulse oximetry_min	0.841153	calcium gluconate	1.895451	tacrolimus	-0.129095
anion gap_std	-0.174407	respiratory rate_min	0.456714	captopril	-0.196582	trazodone	-0.236095
atypical lymphocytes_			0861531	carvedilol	-0.160390	vancomycin	1.755627
bands_std	0.000000	systolic_min	1.350522	cefazolin	-0.160390	vaconiven	-0.136875
basophils_std	0000000	temperature (F)_min	0.874941	cefepime	-0.206430	warfarin	-0.308817
central venous pressure			0.818523	ceftnaxone	-0.227986	zolpidem	-0258922
chloride_std	1.216767	triglycerides_min	0.818546	donazepam	-0.146442	Name: 10903, dtype:	
creatinine_std	-0246752	troponin_min	0.082278	dopidogrel	-0.300981	Name. 10505, dtype.	HUMAN
diastolic_std	1.026489	BUN_max	0.236825	dextrose			
	2.00 200 7020	pour Lands	-		-		-



## Appendix Figure 6: Example Attention Map Patient with Sepsis




Appendix Figure 7: Thresholded Attention Values for Patient with Pyelonephritis




patient variables Appendix 8: (a) Examples of SHAP-generated patient variables driving mortality predictions; (b) top 20 highest importance directional

Evaluation Metric	Mortality	Sepsis	Vancomycin	Myocardial Infarction
AUROC	0.94	0.88	0.83	0.80
F1 Score	86.61	69.98	66.41	37.18
Precision/Positive Predictive Value	82.86	72.23	69.92	25.45
Recall (Sensitivity)/ True Positive Rate	88.55	67.87	63.23	68.96

**Table 1**: Metrics of Evaluation for Deep LSTMs modeling risk of Mortality, Sepsis, Vancomycin, and Myocardial Infarction





Appendix Figure 9: Receiver Operating Characteristic Curves of Mortality at varying times (top) and of sepsis, vancomycin admin, and MI averages among time